Adverse Vascular Functional and Structural Changes Secondary to Breast Cancer and its Treatments with Adjuvant Therapy: a Systematic Review

2021 ◽  
Author(s):  
Alis Bonsignore ◽  
Priya Brahmbhatt ◽  
Daniel Santa Mina ◽  
Jack Goodman ◽  
Maureen Pakosh ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Systematic Review ◽  
Adjuvant Therapy ◽  
Structural Changes

The Clinical Efficacy and Safety of Paclitaxel in Adjuvant Therapy of Breast Cancer: A Systematic Review and Meta-Analysis

2015 ◽  
Vol 4 (2) ◽  
pp. 74-84
Author(s):  
Shao-Hui Cai Shao-Hui Cai ◽  
Hua-Qing Chen ◽  
Yi-Si Li ◽  
Ya-Hua Lin ◽  
Qiu-Tong Tan ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Systematic Review ◽  
Adjuvant Therapy ◽  
Clinical Efficacy ◽  
Meta Analysis ◽  
Efficacy And Safety

Cost-Effectiveness of Trastuzumab as Adjuvant Therapy for Early Breast Cancer: A Systematic Review

2009 ◽  
Vol 43 (2) ◽  
pp. 296-303 ◽  
Author(s):  
Agnes LF Chan ◽  
Henry WC Leung ◽  
Chin-Li Lu ◽  
Shun Jin Lin
Keyword(s):  
Breast Cancer ◽  
Systematic Review ◽  
Cost Effectiveness ◽  
Adjuvant Therapy ◽  
Early Breast Cancer

scholarly journals Bisphosphonates in the adjuvant setting of breast cancer therapy: Effect on survival—A systematic review and meta-analysis.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. 548-548 ◽  
Author(s):  
Liath Vidal ◽  
Irit Ben-Aharon ◽  
Shulamith Rizel ◽  
Rinat Yerushalmi ◽  
Aaron Sulkes ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Systematic Review ◽  
Adjuvant Therapy ◽  
Large Scale ◽  
Meta Analysis ◽  
Cochrane Library ◽  
Control Group ◽  
Adjuvant Setting ◽  
Therapy Effect ◽  
Meta Regression

548 Background: The role of bisphosphonates (BP) in the adjuvant setting in breast cancer has been evaluated in several studies, yielding inconsistent evidence. We performed a systematic review and meta-analysis of all randomized controlled trials (RCTs) that evaluate the effects of BP treatment on survival in patients with early breast cancer in the adjuvant setting. Methods: RCTs that compared BP therapy in addition to the standard adjuvant therapy (cytotoxic or hormonal) with standard adjuvant therapy only were identified by searching the Cochrane Library, LILACS, MEDLINE databases and conference proceedings (12.2011). Hazard ratios (HRs) of overall survival (OS), disease-free survival (DFS) and relative risks of adverse events were estimated and pooled. All statistical tests were two-sided. Results: Thirteen trials met the inclusion criteria., among which are the two recently published abstracts of large scale RCTs (NSABP-B34, GAIN) evaluating a total of 15,762 patients. Ten trials reported the OS outcome. Meta-analysis revealed no statistically significant benefit for BP (HR 0.89, 95% CI = 0.79 to 1.01). Nine trials reported the DFS outcome. Meta-analysis revealed no statistically significant better DFS for the intervention (HR 0.95 (0.80-1.11)). Six trials reported DFS stratified upon menopausal status. Postmenopausal patients who were treated with BP therapy had statistically significant better DFS than the control group (HR 0.81(0.69-0.95)). In meta-regression, chemotherapy was negatively associated with HR of OS (coefficient, -0.23; standard error, 0.144). BP therapy resulted in less fractures in the intervention arm, but higher incidence of osteonecrosis of the jaw and pyrexia. Conclusions: Our meta-analysis indicates a positive effect for adjuvant BP on survival outcomes only in postmenopausal patients with breast cancer. Meta-regression appraised the effect of confounders such as chemotherapy, showed a negative association between chemotherapy use and the effect of bisphosphonates on survival. Further large scale RCTs are warranted to unravel the specific subgroups and adjuvant treatments that would benefit from the addition of BP in the adjuvant setting.

scholarly journals Effectiveness of trastuzumab as adjuvant therapy in patients with early stage breast cancer: A systematic review and meta-analysis

2017 ◽  
Vol 31 (1) ◽  
pp. 515-520 ◽  
Author(s):  
Majid Davari ◽  
Bahman Amani ◽  
Fariborz Mokarian ◽  
Mohsen Hoseini ◽  
Arash Akbarzadeh ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Systematic Review ◽  
Adjuvant Therapy ◽  
Early Stage ◽  
Meta Analysis ◽  
Early Stage Breast Cancer

scholarly journals Adjuvant Therapy With Zoledronic Acid in Patients With Breast Cancer: A Systematic Review and Meta‐Analysis

2013 ◽  
Vol 18 (4) ◽  
pp. 353-361 ◽  
Author(s):  
Antonis Valachis ◽  
Nikolaos P. Polyzos ◽  
Robert E. Coleman ◽  
Michael Gnant ◽  
Holger Eidtmann ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Systematic Review ◽  
Zoledronic Acid ◽  
Adjuvant Therapy ◽  
Meta Analysis

EP1105 The role of stress, age and adjuvant therapy in cognition of patients with breast cancer: a systematic review

2019 ◽  
Author(s):  
A Koumarianou ◽  
A Papanastasiou ◽  
K Kampoli ◽  
E Rizos ◽  
A Ntavatzikos ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Systematic Review ◽  
Adjuvant Therapy

scholarly journals Toxicity of Extended Adjuvant Therapy With Aromatase Inhibitors in Early Breast Cancer: A Systematic Review and Meta-analysis

2017 ◽  
Vol 110 (1) ◽  
pp. 31-39 ◽  
Author(s):  
Hadar Goldvaser ◽  
Tristan A Barnes ◽  
Boštjan Šeruga ◽  
David W Cescon ◽  
Alberto Ocaña ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Systematic Review ◽  
Adjuvant Therapy ◽  
Early Breast Cancer ◽  
Aromatase Inhibitors ◽  
Meta Analysis ◽  
Extended Adjuvant Therapy

scholarly journals Zoledronic Acid as an Adjuvant Therapy in Patients with Breast Cancer: A Systematic Review and Meta-Analysis

PLoS ONE ◽  
2012 ◽  
Vol 7 (7) ◽  
pp. e40783 ◽  
Author(s):  
Wei-Wei Huang ◽  
Cheng Huang ◽  
Jian Liu ◽  
Hong-Yu Zheng ◽  
Lin Lin
Keyword(s):  
Breast Cancer ◽  
Systematic Review ◽  
Zoledronic Acid ◽  
Adjuvant Therapy ◽  
Meta Analysis
Sign in / Sign up

Export Citation Format

Share Document